Meds & supplements › Navepegritide
Medicine
YUVIWEL ® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
YUVIWEL ® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
None.
Storage and Handling
sofidex [Internet]. Daloreum; c2026. Navepegritide; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/navepegritide
sofidex. (2026, August 3). Navepegritide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/navepegritide
Navepegritide. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/navepegritide
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.